Alumis Inc.
ALMS
株式のランク
#9884
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
株価
$6.78
最終同期: 2026-10-21
時価総額
$877.57M
変化（1日）
1.19%
変化（1年）
198.68%
国
US
取引 Alumis Inc. (ALMS)
カテゴリー
Healthcare
Alumis Inc.（ALMS）の株価履歴
終値の最高値: $2.34 （2025-05-01）
終値の最安値: $21.58 （2023-05-01）
終値の最安値: $21.58 （2023-05-01）
Alumis Inc. の株価履歴（2023 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2025 | -35.06% |
| 2024 | -49.49% |
| 2023 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.24 | -4.19% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
